Search

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Jun 12 2015 Posted in Press releases

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

EHA Statement of Solidarity with local communities in Türkiye and Syria

Feb 07 2023 Posted in Press releases

The European Hematology Association (EHA) is deeply concerned about the situation in southern Türkiye and northern Syria: Monday's earthquakes and aftershocks have killed thousands of people and destroyed innumerable buildings, while freezing temperatures and damaged roads are hampering rescue efforts.

Evaluation of a single 1.000 mg iron dose as ferric carboxymaltose (FCM) for fatigue treatment in Iron deficient women – PREFER

Jun 15 2012 Posted in Press releases

Fatigue and iron deficiency are prevalent among women of childbearing age. This randomised, placebo-controlled study evaluated the effect of a single intravenous 1.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

Jun 14 2013

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

Mar 28 2013 Posted in Press releases

What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.

FP9 recommendations BioMed Alliance

Apr 10 2018 Posted in Advocacy news

With preparations under way for the EU’s next Framework Programme for Research and Innovation (FP9), the BioMed Alliance has called for more robust EU support for health research.